270 related articles for article (PubMed ID: 25300869)
1. Veno-occlusive disease of the liver in the absence of elevation in bilirubin in pediatric patients after hematopoietic stem cell transplantation.
Myers KC; Dandoy C; El-Bietar J; Davies SM; Jodele S
Biol Blood Marrow Transplant; 2015 Feb; 21(2):379-81. PubMed ID: 25300869
[TBL] [Abstract][Full Text] [Related]
2. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients.
Myers KC; Lawrence J; Marsh RA; Davies SM; Jodele S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):500-3. PubMed ID: 23211838
[TBL] [Abstract][Full Text] [Related]
3. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
Richardson PG; Murakami C; Jin Z; Warren D; Momtaz P; Hoppensteadt D; Elias AD; Antin JH; Soiffer R; Spitzer T; Avigan D; Bearman SI; Martin PL; Kurtzberg J; Vredenburgh J; Chen AR; Arai S; Vogelsang G; McDonald GB; Guinan EC
Blood; 2002 Dec; 100(13):4337-43. PubMed ID: 12393437
[TBL] [Abstract][Full Text] [Related]
4. Combination of High-Dose Methylprednisolone and Defibrotide for Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplant Recipients.
Gloude NJ; Jodele S; Teusink-Cross A; Grimley M; Davies SM; Lane A; Myers KC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):91-95. PubMed ID: 28939456
[TBL] [Abstract][Full Text] [Related]
5. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Richardson PG; Soiffer RJ; Antin JH; Uno H; Jin Z; Kurtzberg J; Martin PL; Steinbach G; Murray KF; Vogelsang GB; Chen AR; Krishnan A; Kernan NA; Avigan DE; Spitzer TR; Shulman HM; Di Salvo DN; Revta C; Warren D; Momtaz P; Bradwin G; Wei LJ; Iacobelli M; McDonald GB; Guinan EC
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1005-17. PubMed ID: 20167278
[TBL] [Abstract][Full Text] [Related]
6. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
[TBL] [Abstract][Full Text] [Related]
7. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
Richardson PG; Elias AD; Krishnan A; Wheeler C; Nath R; Hoppensteadt D; Kinchla NM; Neuberg D; Waller EK; Antin JH; Soiffer R; Vredenburgh J; Lill M; Woolfrey AE; Bearman SI; Iacobelli M; Fareed J; Guinan EC
Blood; 1998 Aug; 92(3):737-44. PubMed ID: 9680339
[TBL] [Abstract][Full Text] [Related]
8. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
Qureshi A; Marshall L; Lancaster D
Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
[TBL] [Abstract][Full Text] [Related]
9. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research.
Strouse C; Richardson P; Prentice G; Korman S; Hume R; Nejadnik B; Horowitz MM; Saber W
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1306-1312. PubMed ID: 27108694
[TBL] [Abstract][Full Text] [Related]
10. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
[TBL] [Abstract][Full Text] [Related]
12. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
[TBL] [Abstract][Full Text] [Related]
13. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
14. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation.
Chalandon Y; Roosnek E; Mermillod B; Newton A; Ozsahin H; Wacker P; Helg C; Chapuis B
Biol Blood Marrow Transplant; 2004 May; 10(5):347-54. PubMed ID: 15111934
[TBL] [Abstract][Full Text] [Related]
15. The use of defibrotide in blood and marrow transplantation.
Richardson PG; Carreras E; Iacobelli M; Nejadnik B
Blood Adv; 2018 Jun; 2(12):1495-1509. PubMed ID: 29945939
[TBL] [Abstract][Full Text] [Related]
16. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.
Cappelli B; Chiesa R; Evangelio C; Biffi A; Roccia T; Frugnoli I; Biral E; Noè A; Fossati M; Finizio V; Miniero R; Napolitano S; Ferrua F; Soliman C; Ciceri F; Roncarolo MG; Marktel S
Br J Haematol; 2009 Nov; 147(4):554-60. PubMed ID: 19747363
[TBL] [Abstract][Full Text] [Related]
17. High Variability in the Reported Management of Hepatic Veno-Occlusive Disease in Children after Hematopoietic Stem Cell Transplantation.
Skeens MA; McArthur J; Cheifetz IM; Duncan C; Randolph AG; Stanek J; Lehman L; Bajwa R;
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1823-1828. PubMed ID: 27496218
[TBL] [Abstract][Full Text] [Related]
18. Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease.
Triplett BM; Kuttab HI; Kang G; Leung W
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2148-2153. PubMed ID: 26278046
[TBL] [Abstract][Full Text] [Related]
19. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
20. Defibrotide: a review of its use in severe hepatic veno-occlusive disease following haematopoietic stem cell transplantation.
Keating GM
Clin Drug Investig; 2014 Dec; 34(12):895-904. PubMed ID: 25351934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
